Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance.

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

Biktarvy, Gilead's latest triple therapy, was approved by the FDA in February 2018 as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history ...

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are ...

Biktarvy is currently lining Gilead’s pockets as the company’s top-selling drug. For the first three months of 2022, Biktarvy pulled down sales of $2.15 billion worldwide.

Biktarvy sales jumped 18% from 2021's first quarter to $2.15 billion, while Descovy revenues increased 4% to $374 million. On the flip side, Truvada sales took an expected hit, plummeting 72% ...

Biktarvy - Drug Insight, 2019 report provides comprehensive information of the drug, Biktarvy. It includes drugs overview, Biktarvy mechanism of action, clinical trials, regulatory milestones ...

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to ...